Company intelligence / Profile preview
Jubilant HollisterStier
- Ownership
- Public · JUBLPHARMA
- Employees
- ~488
- Development stage
- Commercial
Overview
Jubilant HollisterStier operates as a leading CDMO/CMO with commercial-scale capabilities in sterile fill-finish manufacturing. It has expanded its Spokane facility to double injectable filling capacity by the end of 2025. The allergy division remains a leader in allergenic extract production for nearly a century. No proprietary clinical results are published since it manufactures on behalf of clients.
- Therapeutic areas
- OtherImmunology
- Modalities
- Sterile injectablesophthalmicslyophilized productssterile ointmentsallergenic extractsvaccines including live, mRNA and inactivated/subunit
- Industry
- Biotech
Drug pipeline
24 assets23 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Jubilant HollisterStier.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jubilant HollisterStier.